Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
Key claim: FDA proposes to allow distributed manufacturing establishments operating across multiple physical locations to register as a single entity and to align foreign drug establishment registration rules with the PREVENT Pandemics Act.
Abstract
(Proposed Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend the drug establishment registration and drug listing requirements with respect to establishments engaged in distributed manufacturing and foreign drug establishments. This action, if finalized, will provide a pathway for a distributed manufacturing establishment that manufactures drugs at multiple different physical locations to register as a single drug manufacturing establishment and align drug establishment registration and drug listing regulations applicable to foreign drug establishments with statutory changes made by the Preparing for and Responding to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act).
Why this matters
Establishment registration and drug listing are the foundational visibility tools FDA uses to know who makes what drugs and where, which underpins inspections, shortage response, and import oversight. Allowing distributed manufacturing sites to register as a single entity acknowledges newer production models (including continuous and modular manufacturing) that don’t fit the traditional one-facility framework. Aligning foreign establishment rules with the PREVENT Pandemics Act closes a statutory gap that affects how overseas suppliers of U.S. drugs are tracked.